CEACAM5 and peritoneum cancer: Patients with clinical and radiological evidence of stage III or IV EOC, tubal or peritoneal cancer and a CA-125 to CEA ratio >25 were randomised either to receive PDS followed by 6 cycles of platinum-based chemotherapy or 3 cycles of platinum-based chemotherapy followed by IDS and a final 3-cycle platinum-based chemotherapy regimen.